Drugs / LY2599666
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02614131 | Dec 2015 → Dec 2016 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2599666 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02614131 ↗ |
| Route | Subcutaneous | “LY2599666 given subcutaneously (SC) once.” NCT02614131 ↗ |